跳至主要内容
临床试验/NL-OMON50640
NL-OMON50640招募中3 期

HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD; a randomized phase III trial - HD21 (advanced stage)

niversitly of Cologne0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Histologically proven classical Hodgkin lymphoma
  • - First diagnosis, no previous treatment
  • - 18 to 60 years of age; cohort elderly: 61-75 years
  • - Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or

排除标准

  • - Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma
  • -Previous malignancy (exceptions: basalioma, carcinoma in situ of the cervix
  • uteri, completely resected melanoma TNMpT1)
  • - Prior chemotherapy or radiotherapy
  • - Concurrent disease which precludes protocol treatment
  • - Pregnancy, lactation
  • - Non-Compliance

研究者

发起方
niversitly of Cologne

相似试验

HD21 for advanced stages: Treatment optimization... | 临床试验